Preclinical drug discovery for new anti-pneumocystis compounds

Current Medicinal Chemistry

Volumn 16, Issue 20, 2009, Pages 2514-2530

  Cushion, Melanie T ^a,b   Walzer, Peter D ^a,b  

^a Veterans Administration Getting   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Applicability to humans; Cell free systems; Drug development; In vitro testing; In vivo testing; Mouse and rat models; Pneumocystis pneumonia (PCP); Treatment and prophylaxis

Indexed keywords

2,5 BIS(4 AMIDINOPHENYL)FURAN; 4 AMINOBENZOIC ACID; ADENOSINE TRIPHOSPHATE; ANTIINFECTIVE AGENT; ATOVAQUONE; BERBERINE; BETA GLUCAN SYNTHASE INHIBITOR; CASPOFUNGIN; CERULENIN; COTRIMOXAZOLE; DAPSONE; DIHYDROFOLATE REDUCTASE INHIBITOR; DIHYDROPTEROATE SYNTHASE; DNA TOPOISOMERASE INHIBITOR; ECHINOCANDIN; ENZYME INHIBITOR; FOLIC ACID ANTAGONIST; LANOSTEROL SYNTHASE INHIBITOR; PAFURAMIDINE; PENTAMIDINE; PENTAMIDINE ISETHIONATE; PROTEINASE INHIBITOR; PYRIMETHAMINE; PYRIMETHAMINE SULFADIAZINE; SIMVASTATIN; SORDARIN DERIVATIVE; SQUALENE SYNTHASE; STEROL DERIVATIVE; TOLNAFTATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CANDIDIASIS; CELL FREE SYSTEM; CELL VIABILITY; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENTIATION; DRUG PURIFICATION; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; EXPERIMENTAL MOUSE; EXPERIMENTAL RAT; FUNGAL LIFE CYCLE STAGE; HETEROLOGOUS EXPRESSION; HUMAN; HYPOGLYCEMIA; HYPOTENSION; IC 50; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; INTERSTITIAL PNEUMONIA; LIFE CYCLE; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; PNEUMOCYSTIS; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; REVIEW; THROMBOCYTOPENIA;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; ANTIFUNGAL AGENTS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; HUMANS; LIFE CYCLE STAGES; PNEUMOCYSTIS; PNEUMONIA, PNEUMOCYSTIS;

EID: 70349383029     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709788682038     Document Type: Review

References (201)

1. Alder, J.; Mitten, M.; Shipkowitz, N.; Hernandez, L.; Hui, L.Y.; Marsh, K.; Clement, J. Treatment of experimental Pneumocystis carinii infection by combination of clarithromycin and sulphamethoxazole. J. Antimicrob. Chemother., 1994, 33, 253-263.
2. Allegra, C. J.; Kovacs, J.A.; Drake, J.C.; Swan, J.C.; Chabner, B.A, Masur, H. Activity of antifolates against Pneumocystis carinii dihydrofolate reductase and identification of a potent new agent. J. Exp. Med., 1987, 165, 926.
3. Ivady, G.; Paldy, L.; Koltay, M.; Toth, G.; Kovacs, Z. Pneumocystis carinii pneumonia. Lancet, 1967, 1, 616-617
4. Walzer, P. D.; Perl, D. P.; Krogstad, D. J.; Rawson, P. G.; Schultz, M.G. Pneumocystis carinii pneumonia in the United States. Epidemiologic, diagnostic, and clinical features. Ann. Intern. Med., 1974, 80, 83-93.
5. Frenkel, J.K.; Good, J.T.; Shultz, J.A. Latent Pneumocystis infection of rats, relapse, and chemotherapy. Lab. Invest., 1966, 15, 1559-1577.
6. Hughes, W.T.; McNabb, P.C.; Makres, T.D.; Feldman, S. Efficacy of trimethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonitis. Antimicrob. Agents Chemother., 1974, 5, 289-293.
7. Redhead, S.A.; Cushion, M.T.; Frenkel, J.K.; Stringer, J.R. Pneumocystis and Trypanosoma cruzi: Nomenclature and typifications. J. Eukaryot. Microbiol., 2006, 53, 2-11.
8. Frenkel, J. K. Pneumocystis pneumonia, an immunodeficiency-dependent disease (IDD): A critical historical overview. J. Eukaryot. Microbiol., 1999, 46, 89S-92S.
9. Cushion, M.T.; Keely, S. P.; Stringer, J.R. Validation of the name Pneumocystis wakefieldiae. Mycologia, 2005, 97, 268.
10. Cushion, M.T.; Zhang, J.; Kaselis, M.; Giuntoli, D.; Stringer, S.L.; Stringer, J.R. Evidence for two genetic variants of Pneumocystis carinii coinfecting laboratory rats. J. Clin. Microbiol., 1993, 31, 1217-1223.
11. Icenhour, C.R.; Arnold, J.; Medvedovic, M.; Cushion, M.T. Competitive coexistence of two Pneumocystis species. Infect. Genet. Evol., 2006, 6, 177-186.
12. Keely, S.P.; Fischer, J.M.; Cushion, M.T.; Stringer, J.R. Phylogenetic identification of Pneumocystis murina sp. nov.; a new species in laboratory mice. Microbiology, 2004, 150, 1153-1165.
13. Dei-Cas, E.; Chabe, M.; Moukhlis, R.; Durand-Joly, I.; Aliouat, E.M.; Stringer, J.R.; Cushion, M.; Noel, C.; Sybren, D.H.; Guillot, J.; Viscogliosi, E. Pneumocystis oryctolagi sp. nov., an uncultured fungus causing pneumonia in rabbits at weaning: Review of current knowledge, and description of a new taxon on genotypic, phyloge netic and phenotypic bases. FEMS Microbiol., 2006, Rev 30, 853-871.
14. Walzer, P.D.; Foy, J.; Steele, P.; White, M. Treatment of experimental pneumocystosis: Review of 7 years of experience and development of a new system for classifying antimicrobial drugs. Antimicrob. Agents Chemother., 1992, 36, 1943-1950.
15. Cushion, M. T. Pneumocystis pneumonia, 2006, p. 763-806. In W. G. Merz and R. J. Hay (eds.), Topley & Wilson's Medical Mycology. Edward Arnold Ltd., Washington, D.C.
16. Cushion, M.T.; Smulian, A.G.; Slaven, B.E.; Sesterhenn,T.; Arnold, J.; Staben, C.; Porollo, A.; Adamczak, R.; Meller, J. Transcriptome of Pneumocystis carinii during fulminate infection: Carbohydrate metabolism and the concept of a compatible parasite. PLoSOne, 2007, 2, e423.
17. Collins, M.S.; Cushion, M.T. Standardization of an in vitro drug screening assay by use of cryopreserved and characterized Pneumocystis carinii populations. J. Eukaryot. Microbiol., 2001, Suppl, 178S-179S.
18. Gangjee, A.; Adair, O.; Queener, S.F. Synthesis of 2,4-diamino-6-(thioarylmethyl)pyrido2,3-dpyrimidines as dihydrofolate reductase inhibitors. Bioorg. Med. Chem., 2001, 9, 2929-2935.
19. Gangjee, A.; Guo, X.; Queener, S.F.; Cody, V.; Galitsky, V.; Luft, J.R.; Pangborn, W. Selective Pneumocystis carinii dihydrofolate reductase inhibitors: Design, synthesis, and biological evaluation of new 2,4-diamino-5-substituted-furo[2,3-d] pyrimidines. J. Med. Chem., 1998, 41, 1263-1271.
20. Gangjee, A.; Mavandadi, F.; Kisliuk, R.L.; Queener, S.F. Synthesis of classical and a nonclassical 2-amino-4-oxo-6-methyl-5-substituted pyrrolo[2,3-]dpyrimidine antifolate inhibitors of thymidylate synthase. J. Med. Chem., 1999, 42, 2272-2279.
21. Gangjee, A.; Zhu, Y.; Queener, S.F. 6-Substituted 2,4-diaminopyrido[3,2-d]pyrimidine analogues of piritrexim as inhibitors of dihydrofolate reductase from rat liver, Pneumocystis carinii, and Toxoplasma gondii and as antitumor agents. J. Med. Chem., 1998, 41, 4533-4541.
22. Rosowsky, A.; Forsch, R.A.; Queener, S.F. Further studies on 2,4-diamino-5-(2′,5′-disubstituted benzyl) pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS. J. Med. Chem., 2003, 46, 1726-1736.
23. Meneau, I.; Sanglard, D.; Bille, J.; Hauser, P.M. Pneumocystis jiroveci dihydropteroate synthase polymorphisms confer resistance to sulfadoxine and sulfanilamide in Saccharomyces cerevisiae. Antimicrob. Agents. Chemother., 2004, 48, 2610-2616.
24. Cushion, M. T. In vitro studies of Pneumocystis carinii. J. Protozool., 1989, 36, 45-52.
25. Atzori, C.; Angeli, E.; Agostoni, F.; Mainini, A.; Filippini, M.; Cargnel, A. In vitro drug assays and statistical analysis. FEMS Immunol. Med. Microbiol., 1998, 22, 181-183.
26. Bartlett, M.S.; Edlind, T.D.; Durkin, M.M.; Shaw, M.M.; Queener, S.F.; Smith, J.W. Antimicrotubule benzimidazoles inhibit in vitro growth of Pneumocystis carinii. Antimicrob Agents Chemother., 1992, 36, 779-782.
27. Cirioni, O.; Giacometti, A.; Barchiesi, F.; Scalise, G. In-vitro activity of lytic peptides alone and in combination with macrolides and inhibitors of dihydrofolate reductase against Pneumocystis carinii. J. Antimicrob. Chemother., 1998, 42, 445-451.
28. Cirioni, O.; Giacometti, A.; Barchiesi, F.; Fortuna, M.; Scalise, G. In-vitro activity of rifabutin and albendazole singly and in combination with other clinically used antimicrobial agents against Pneumocystis carinii. J. Antimicrob. Chemother., 1999, 44, 653-659.
29. Cirioni, O.; Giacometti, A.; Barchiesi, F.; Scalise, G. Inhibition of growth of Pneumocystis carinii by lactoferrins alone and in combination with pyrimethamine, clarithromycin and minocycline. J. Antimicrob. Chemother., 2000, 46, 577-582.
30. Contini, C.; Manganaro, M.; Romani, R.; Tzantzoglou, S.; Poggesi, I.; Vullo, V.; Delia, S.; De Simone, D. Activity of terbinafine against Pneumocystis carinii in vitro and its efficacy in the treatment of experimental pneumonia. J. Antimicrob. Chemother., 1994, 34, 727-735.
31. Merali, S.; Meshnick, R. Susceptibility of Pneumocystis carinii to artemisinin in vitro. Antimicrob. Agents Chemother., 1991, 35, 1225-1227.
32. Durkin, M.M.; Bartlett, M.S.; Queener, S.F.; Shaw, M.M.; Lee, C.H.; Smith, J.W. An ELISA method for quantitation of Pneumocystis carinii in culture and lung. J. Protozool., 1991, 38, 208S-210S.
33. Atzori, C.; Fantoni, G.; Valerio, A.; Cargnel, A. In vitro activity of amprenavir against Pneumocystis carinii. Int. J. Antimicrob. Agents., 2001, 18, 271-273.
34. Cushion, M.T.; Ruffolo, J.J.; Linke, M.J.; Walzer, P.D. Pneumocystis carinii: Growth variables and estimates in the A549 and WI-38 VA13 human cell lines. Exp. Parasitol., 1985, 60, 43-54.
35. Cushion, M.T.; Ruffolo, J.J.;Walzer, P.D. Analysis of the developmental stages of Pneumocystis carinii, in vitro. Lab. Invest., 1988, 58, 324-331.
36. Cushion, M.T.; Stanforth, D.; Linke, M.J.; Walzer, P.W. Method of testing the susceptibility of Pneumocystis carinii to antimicrobial agents in vitro. Antimicrob. Agents Chemother., 1985, 28, 796-801.
37. Cushion, M.T.;Walzer, P.D. Growth and serial passage of Pneumocystis carinii in the A549 cell line. Infect. Immun., 1984, 44, 245-251.
38. Cushion, M.T. Pneumocystis, In Murray, P.R.; Baron, E.J.; Jorgensen, J.; Pfaller, M.; Landry, M.L. (eds.), Manual of Clinical Microbiology. ASM Press, Washington, DC. 2007.
39. Chen, F.; Cushion, M.T. Use of an ATP bioluminescent assay to evaluate viability of Pneumocystis carinii from rats. J. Clin. Microbiol., 1994, 32, 2791-2800.
40. Cushion, M.T.; Chen, F.; Kloepfer, N. A cytotoxicity assay for evaluation of candidate anti-Pneumocystis carinii agents. Antimicrob. Agents. Chemother., 1997, 41, 379-384
41. Anonymous. Update on Kaposi's sarcoma and opportunistic infections in previously healthy persons-United States. MMWR, 1982, 31, 294, 300-294, 301.
42. Broughton, M.C.; Queener, S.F. Pneumocystis carinii dihydrofolate reductase used to screen potential antipneumocystis drugs. Antimicrob. Agents Chemother., 1991, 35, 1348-1355
43. Merali, S.; Zhang, Y.; Sloan, D.; Meshnick, H.S. Inhibition of Pneumocystis carinii dihydropteroate synthetase by sulfa drugs. Antimicrob. Agents Chemother., 1990, 34, 1075-1078
44. Dykstra, C.C.; McClernon, D.R.; Elwell, L.P.; Tidwell, R.R. Selective inhibition of topoisomerases from Pneumocystis carinii compared with that of topoisomerases from mammalian cells. Antimicrob. Agents Chemother., 1994, 38, 1890-1898.
45. Hong, Y.L.; Hossler, P.A.; Calhoun, D.H.; Meshnick, S.R. Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs. Antimicrob. Agents Chemother., 1995, 39, 1756-1763.
46. Van Dross, R.T. Sanders, M.M. Molecular Characterization of Recombinant Pneumocystis carinii Topoisomerase I: Differential Interactions with Human Topoisomerase I Poisons and Pentamidine. Antimicrob. Agents Chemother., 2004, 6, 2145-2154.
47. Wang, Y.; Bruenn, J.A.; Queener, S.F.; Cody, V. Isolation of rat dihydrofolate reductase gene and characterization of recombinant enzyme. Antimicrob. Agents Chemother., 2001, 45, 2517-2523.
48. Bartlett, M.S.; Shaw, M.; Navaran, P.; Smith, J.W.; Queener, S.F. Evaluation of potent inhibitors of dihydrofolate reductase in a culture model for growth of Pneumocystis carinii. Antimicrob. Agents Chemother., 1995, 39, 2436-2441.
49. Gangjee, A.; Adair, O.O.; Queener, S.F. Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido2,3-dpyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents. J. Med. Chem., 2003, 46, 5074-5082.
50. Gangjee, A.; Yang, J.; Queener, S.F. Novel non-classical C9-methyl-5-substituted-2,4-diaminopyrrolo[2,3-d]pyrimidines as potential inhibitors of dihydrofolate reductase and as antiopportunistic agents. Bioorg. Med. Chem., 2006, 14, 8341-8351
51. Gangjee, A.; Yu, J, McGuire, J.J.; Cody, V.; Galitsky, N.; Kisliuk, R.L.; Queener, S.F. Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent. J. Med. Chem., 2000, 43, 3837-3851.
52. Chio, L.C.; Bolyard, L.A.; Nasr, M.; Queener, S.F. Identification of a class of sulfonamides highly active against dihydropteroate synthase form Toxoplasma gondii, Pneumocystis carinii, and Mycobacterium avium. Antimicrob. Agents Chemother., 1996, 40, 727-733.
53. Volpe, F.; Ballantine, S.P.; Delves, C.J. The multifunctional folic acid synthesis fas gene of Pneumocystis carinii encodes dihydroneopterin aldolase, hydroxymethyldihydropterin pyrophos-phokinase and dihydropteroate synthase. Eur. J. Biochem., 1993, 216, 449-458.
54. Fishman, J.A.; Queener, S.F.; Roth, R.S.; Bartlett, M.S. Activity of topoisomerase inhibitors against Pneumocystis carinii in vitro and in an inoculated mouse model. Antimicrob. Agents Chemother., 1993, 37, 1543-1546.
55. Ashbaugh, A.; Cushion, M. T.; Collins, M. S.; Rebholz, S.; Walzer, P. D. In vivo Efficacy of echinocandins in a mouse model of Pneumocystis murina pneumonia. Am. J. Resp. Critic Care Med., 2007, (Abstract Issue) 175, A857.
56. Kazanjian, P.; Armstrong, W.; Hossler, P.A.; Burman, W.; Richardson, J.; Lee, C.H.; Crane, L.; Katz, J.; Meshnick, S.R. Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. J. Infect. Dis., 2000, 182, 551-557.
57. Kazanjian, P.H.; Fisk, D.; Armstrong, W.; Shulin, Q.; Liwei, H.; Ke, Z.; Meshnick, S. Increase in prevalence of Pneumocystis carinii mutations in patients with AIDS and P. carinii pneumonia, in the United States and China. J. Infect. Dis., 2004, 189, 1684-1687.
58. Stein, C.R.; Poole, C.; Kazanjian, P.; Meshnick, S.R. Sulfa use, dihydropteroate synthase mutations, and Pneumocystis jirovecii pneumonia. Emerg. Infect. Dis., 2004, 10, 1760-1765.
59. Ma, L.; Borio, L.; Masur, H.; Kovacs, J.A. Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use. J. Infect. Dis., 1999, 180, 1969-1978.
60. Armstrong, W.; Meshnick, S.; Kazanjian, P. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in immunocompromised patients. Microbes. Infect., 2000, 2, 61.
61. Kovacs, J.A.; Gill, V.J.; Meshnick, S.R.; Masur, H. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA, 2001, 286, 2450-2460.
62. Iliades, P.; Meshnick, S.R.; Macreadie, I.G. Dihydropteroate Synthase Mutations in Pneumocystis jiroveci can affect sulfamethoxazole resistance in a Saccharomyces cerevisiae model. Antimicrob. Agents Chemother., 2004, 48, 2617-2623.
63. Cushion, M.T.; Ebbets, D. Growth and metabolism of Pneumocystis carinii in axenic culture. J. Clin. Microbiol., 1990, 28, 1385-1394.
64. Martinez, A.; Kovacs, J.A. Development and characterization of a rapid screening assay for identifying antipneumocystis agents. Antimicrob. Agents Chemother., 1993, 37, 1674-1678
65. Cushion, M.T.; Collins, M.; Hazra, B.; Kaneshiro, E.S. Effects of atovaquone and diospyrin-based drugs on the cellular ATP of Pneumocystis carinii f. sp. carinii. Antimicrob. Agents Chemother., 2000, 44, 713-719.
66. Kaneshiro, E.S.; Collins, M.S.; Cushion, M.T. Inhibitors of sterol biosynthesis and amphotericin B reduce the viability of Pneumocystis carinii f. sp. carinii. Antimicrob. Agents Chemother., 2000, 44, 1630-1638.
67. Kuzmits, R.; Aiginger, P.; Muller, M.M.; Steurer, G.; Linkesch, W. Assessment of the sensitivity of leukaemic cells to cytotoxic drugs by bioluminescence measurement of ATP in cultured cells. Clin. Sci. (Lond), 1986, 71, 81-88.
68. Kuzmits, R.; Rumpold, H.; Muller, M.M.; Schopf, G. The use of bioluminescence to evaluate the influence of chemotherapeutic drugs on ATP-levels of malignant cell lines. J. Clin. Chem. Clin. Biochem., 1986, 24, 293-298.
69. Prioli, R.P.; Tanna, A.; Brown, I.N. Rapid methods for counting mycobacteria - comparison of methods for extraction of mycobacterial adenosine triphosphate (ATP) determined by firefly luciferase assay. Tubercle, 1985, 66, 99-108.
70. Sevin, B.U.; Peng, Z.L.; Perras, J.P.; Ganjei, P.; Penalver, M.; Averette, H.E. Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing. Gynecol. Oncol., 1988, 31, 191-204.
71. Cushion, M. T.; Walzer, P.D.; Ashbaugh, A.; Rebholz, S.; Brubaker, R.; Vanden Eynde, J.J.; Mayence, A.; Huang, T.L. In vitro selection and in vivo efficacy of piperazine- and alkanediamide-linked bisbenzamidines against Pneumocystis pneumonia in mice. Antimicrob. Agents Chemother., 2006, 50, 2337-2343
72. Tidwell, R.R.; Jones, S.K.; Dykstra, C.C.; Gorton, L.; Hall, J.E. Treatment of experimental Pneumocystis carinii pneumonia with 1,3-di(4-imidazolino-2-methoxyphenoxy)propane lactate. J. Protozool., 1991, 38, 148S-150S.
73. Hughes, W.T.; Feldman, S.; Chaudhary, S.C.; Ossi, M.J.; Cox, F.; Sanyal, S.K. Comparison of pentamidine isethionate and trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia. J. Pediatr., 1978, 92, 285-291.
74. Lanteri, C.A.; Trumpower, B.L.; Tidwell, R.R.; Meshnick, S.R. DB75, a novel trypanocidal agent, disrupts mitochondrial function in Saccharomyces cerevisiae. Antimicrob. Agents Chemother., 2004, 48, 3968-3974.
75. Cushion, M.T.; Walzer, P.D.; Collins, M.S.; Rebholz, S.; Vanden Eynde, J.J.; Mayence, A.; Huang, T.L. Highly active anti-Pneumocystis carinii compounds in a library of novel piperazine-linked bisbenzamidines and related compounds. Antimicrob. Agents Chemother., 2004, 48, 4209-4216.
76. Vanden Eynde, J. J.; Mayence, A.; Huang, T.L.; Collins, M.S.; Rebholz, S.; Walzer, P.D.; Cushion, M.T. Novel bisbenzamidines as potential drug candidates for the treatment of Pneumocystis carinii pneumonia. Bioorg. Med. Chem. Lett., 2004, 14, 4545-4548.
77. Atzori, C.; Angeli, E.; Mainini, A.; Agostoni, F.; Micheli, V.; Cargnel, A. In vitro activity of human immunodeficiency virus protease inhibitors against Pneumocystis carinii. J. Infect. Dis., 2000, 181, 1629-1634.
78. Walzer, P.D.; Ashbaugh, A.; Collins, M.; Cushion, M.T. Anti-human immunodeficiency virus drugs are ineffective against Pneumocystis carinii in vitro and in vivo. J. Infect. Dis., 2001, 184, 1355-1357.
79. Herreros, E.; Almela, M.J.; Lozano, S.; Gomez, F.; De Las Heras, Gargallo-Viola, D. Antifungal activities and cytotoxicity studies of six new azasordarins. Antimicrob. Agents Chemother., 2001, 45, 3132-3139.
80. Aviles, P.; Aliouat, E.M.; Martinez, A.; Dei-Cas, E.; Herreros, E.; Dujardin, L.; Gargallo-Viola, D. In vitro pharmacodynamic parameters of sordarin derivatives in comparison with those of marketed compounds against Pneumocystis carinii isolated from rats. Antimicrob. Agents Chemother., 2000, 44, 284-1290.
81. Schmatz, D.M.; Romancheck, M.A.; Pittarelli, L.A.; Schwartz, R.E.; Fromtling, R.A.; Nollstadt, K.H.; Vanmiddlesworth, F.L.; Wilson, K.E.; Turner, M.J. Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors. Proc. Natl. Acad. Sci. USA, 1990, 87, 5950-5954.
82. Odabasi, Z.; Paetznick, V.; Rex, J.H.; Ostrosky-Zeichner, L. Effects of serum on In vitro susceptibility testing of echinocandins. Antimicrob. Agents Chemother., 2007, 51, 4214-4216
83. [Centers for Disease Control and Prevention. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. MMWR early release 2009, 58, 1-207.
84. Green, H.; Paul, M.; Vidal, L.; Leibovici, L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: Systematic review and meta-analysis of randomized controlled trials. Mayo Clin. Proc., 2007, 82, 1052-1059.
85. Icenhour, C.R.; Rebholz, S.L.; Collins, M.S.; Cushion, M.T. Widespread occurrence of Pneumocystis carinii in commercial rat colonies detected using targeted PCR and oral swabs. J. Clin. Microbiol., 2001, 39, 3437-3441.
86. Weisbroth, S.H.; Geistfeld, J.; Weisbroth, S.P.; Williams, B.; Feldman, S.H.; Linke, M.J.; Orr, S.; Cushion, M.T. Latent Pneumocystis carinii infection in commercial rat colonies: Comparison of inductive immunosuppressants plus histopathology, PCR, and serology as detection methods. J. Clin. Microbiol., 1999, 37, 1441- 446.
87. O'Leary, T.J.; Tsai, M.M.; Wright, C.F.; Cushion, M.T. Use of semiquantitative PCR to assess onset and treatment of Pneumocystis carinii infection in rat model. J. Clin. Microbiol., 1995, 33, 718-724.
88. Boylan, C.J. Current, W.L. Improved rat model of Pneumocystis carinii pneumonia: Induced laboratory infections in Pneumocystis-free animals. Infect. Immun., 1992, 60, 1589-1597.
89. Powles, M.A.; McFadden, D.C.; Pittarelli,L.A.; Schmatz, D.M. Mouse model for Pneumocystis carinii pneumonia that uses natural transmission to initiate infection. Infect. Immun., 1992, 60, 1397-1400.
90. Ueda, K.; Goto, Y.; Yamazaki, S.; Fujiwara. K. Chronic fatal pneumocystosis in nude mice. Jpn. J. Exp. Med., 1977, 47, 475-482.
91. Walzer, P.D.; Powell, Jr.; R.D.; Yoneda, K. Experimental Pneumocystis carinii pneumonia in different strains of cortisonized mice. Infect. Immun., 1979, 24, 939-947.
92. Walzer, P.D.; Runck, J.; Steele, P.; White, M.; Linke, M.J.; Sidman, C.J. Immunodeficient and immunosuppressed mice as models to test anti- Pneumocystis carinii drugs. Antimicrob. Agents Chemother., 1997, 41, 251-258.
93. Bray, M.V.; Barthold, S.W.; Sidman, C.L.; Roths, J.; Smith, A.L. Exacerbation of Pneumocystis carinii pneumonia in immunodeficient (scid) mice by concurrent infection with a pneumovirus. Infect. Immun., 1993, 61, 1586-1588.
94. Harmsen, A.G.; Stankiewicz, M. Requirement for CD4+ cells in resistance to Pneumocystis carinii pneumonia in mice. J. Exp. Med., 1990, 172, 937-945.
95. McFadden, D.C.; Powles, M.A.; Smith, J.G.; Flattery, A.M.; Bartizal, K.; Schmatz, D. Use of anti-CD4+ hybridoma cells to induce Pneumocystis carinii in mice. Infect. Immun., 1994, 62, 4887-4892.
96. Roths, J.B.; Marshall, J.D.; Allen, R.D.; Carlson, G.A.; Sidman, C.L. Spontaneous Pneumocystis carinii pneumonia in immunodeficient mutant scid mice. Natural history and pathobiology. Am. J. Pathol., 1990, 136, 1173-1186.
97. Roths, J.B.; Sidman, C.L. Single and combined humoral and cell-mediated immunotherapy of Pneumocystis carinii pneumonia in immunodeficient scid mice. Infect. Immun., 1993, 61, 1641-1649
98. Shellito, J.; Suzara, V.; Blumenfeld, W.; Beck, J.M.; Steger, H.J.; Ermak, T.H. A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes. J. Clin. Invest., 1990, 85, 1686-1693.
99. Shultz, L.D.; Schweitzer, P.A.; Hall, E.J.; Sundberg, J.P.; Taylor, S.; Walzer, P.D. Pneumocystis carinii pneumonia in scid/scid mice. Curr. Top. Microbiol. Immunol., 1989, 152, 243-249
100. Sidman, C.L.; Roths, J.B. New animals for Pneumocystis carinii research: Immunodeficient mice, In P. D. Walzer (ed.), Pneumocystis carinii pneumonia. Marcel-Dekker, New York. 1994, pp. 223-236.
101. Comley, J.C.; Sterling, A.M. Artificial infections of Pneumocystis carinii in the SCID mouse and their use in the in vivo evaluation of antipneumocystis drugs. J. Eukaryot. Microbiol., 1994, 41, 540-546.
102. Bartlett, M.S.; Edlind, T.D.; Lee, C.H.; Dean, R.; Queener, S.F.; Shaw, M.M.; Smith, J.W. Albendazole inhibits Pneumocystis carinii proliferation in inoculated immunosuppressed mice. Antimicrob. Agents Chemother. 1994, 38, 1834-1837.
103. Walzer, P.D. Development of new anti-Pneumocystis carinii drugs: cumulative experience at a single institution. In P. D. Walzer (ed.), Pneumocystis carinii pneumonia. Marcel-Dekker, New York. 1994, pp. 511-544.
104. Walzer, P.D.; Kim, D.K.; Cushion, M.T. Pneumocystis carinii, In P. D. Walzer and R. M. Genta (eds.), Parasitic infections in the immunocompromised host. Marcel-Dekker, New York. 1989, pp. 83-178.
105. Morris, S.A.; Schwartz, R.E.; Sesin, D.F.; Masurekar, P.; Hallada, T.C.; Schmatz, D.M.; Bartizal, K.; Hensens, O.D.; Zink, D.L. Pneumocandin D0, a new antifungal agent and potent inhibitor of Pneumocystis carinii. J. Antibiot. (Tokyo), 1994, 47, 755-764.
106. Powles, M.A.; McFadden, D.C.; Liberator, P.A.; Anderson, J.W.; Vadas, E.B.; Meisner, D.; Schmatz, D.M. Aerosolized L-693,989 for Pneumocystis carinii prophylaxis in rats. Antimicrob. Agents Chemother., 1994, 38, 1397-1401.
107. Schmatz, D.M.; Abruzzo, G.; Powles, M.A.; McFadden, D.C.; Balkovec, J.M.; Black, R.M.; Nollstadt, K.; Bartizal, K. Pneumocandins from Zalerion arboricola. IV. Biological evaluation of natural and semisynthetic pneumocandins for activity against Pneumocystis carinii and Candida species. J. Antibiot. (Tokyo), 1992, 45, 1886-1891.
108. Schmatz, D.M.; Powles, M.; McFadden, D.C.; Pittarelli, L.A.; Liberator, P.A.; Anderson, J.W. Treatment and prevention of Pneumocystis carinii pneumonia and further elucidation of the P. carinii life cycle with 1,3-beta-glucan synthesis inhibitor L-671,329. J. Protozool., 1991, 38, 151S-153S.
109. Schmatz, D.M.; Powles, M.A.; McFadden, D.; Nollstadt, K.; Bouffard, F.A.; Dropinski, J.F.; Liberator, P.; Andersen, J. New semisynthetic pneumocandins with improved efficacies against Pneumocystis carinii in the rat. Antimicrob. Agents Chemother., 1995, 39, 1320-1323.
110. Larsen, H.H.; Kovacs, J.A.; Stock, F.; Vestereng, V.H.; Lundgren, B.; Fischer, S.H.; Gill, V.J. Development of a rapid real-time PCR assay for quantitation of Pneumocystis carinii f. sp. carinii. J. Clin. Microbiol., 2002, 40, 2989-2993.
111. D'Antonio, R.G.; Johnson, D.B.; Winn, R.E.; van Dellen, A.F.; Evans, M.E. Effect of folinic acid on the capacity of trimethoprimsulfamethoxazole to prevent and treat Pneumocystis carinii pneumonia in rats. Antimicrob. Agents Chemother., 1986, 29, 327-329.
112. gonzalez-Ruiz, A.; Haworth, S.J.; O'Neil, A.B.; Warhurst, D.C. Dapsone in low doses prevents Pneumocystis carinii pneumonia in the rat model. J. Infect., 1991, 22, 143-152.
113. Hussain, Z.; Carlson, M.L.; Craig, I.D.; Lannigan, R. Efficacy of tetroxoprim/sulphadiazine in the treatment of Pneumocystis carinii pneumonitis in rats. J. Antimicrob. Chemother., 1985, 15, 575-578.
114. Kluge, R.M.; Spaulding, D.M.; Spain, A.J.; Combination of pentamidine and trimethoprim-sulfamethoxazole in therapy of Pneumocystis carinii pneumonia in rats. Antimicrob. Agents Chemother., 1978, 13, 975-978.
115. Kovacs, J.A.; Allegra, C.J.; Kennedy, S.; Swan, J.C.; Drake, J.; Parrillo, J.E.; Chabner, B.; Masur, H. Efficacy of trimetrexate, a potent lipid-soluble antifolate, in the treatment of rodent Pneumocystis carinii pneumonia. Am. J. Trop. Med. Hyg., 1988, 39, 491-496.
116. Queener, S.F.; Bartlett, M.S.; Jay, M.A.; Durkin, M.M.; Smith, J.W. Activity of lipid-soluble inhibitors of dihydrofolate reductase against Pneumocystis carinii in culture and in a rat model of infection. Antimicrob. Agents Chemother., 1987, 31, 1323-1327.
117. Walzer, P.D.; Foy, J.; Steele, P.; Kim, C.K.; White, M.; Klein, R.S.; Otter, B.A.; Allegra, C. Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother., 1992, 36, 1935-1942.
118. Walzer, P.D.; Kim, C.K.; Foy, J.M.; Linke, M.J.; Cushion, M.T. Inhibitors of folic acid synthesis in the treatment of experimental Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother., 1988, 32, 96-103.
119. nonymous, Update on acquired immune deficiency syndrome (AIDS) - United States. MMWR, 1982, 31, 507-614.
120. Hughes, W.T. Macrolide-antifol synergism in anti-Pneumocystis carinii therapeutics. J. Protozool., 1991, 38, 160S.
121. Hughes, W.T.; Killmar, J.T. Synergistic anti-Pneumocystis carinii effects of erythromycin and sulfisoxazole. J. Acquir. Immune. Defic. Syndr., 1991, 4, 532-537.
122. Boykin, D.W.; Kumar, A.; Spychala, J.; Zhou, M.; Lombardy, R.J.; Wilson, W.D.; Dykstra, C.C.; Jones, S.K.; Hall, J.E.; Tidwell, R.R. Dicationic diarylfurans as anti-Pneumocystis carinii agents. J. Med. Chem., 1995, 38, 912-916.
123. Boykin, D.W.; Kumar, A.; Xiao, G.; Wilson, W.D.; Bender, B.C.; McCurdy, D.R.; Hall, J.E.; Tidwell, R.R. 2,5-bis[4-(N-alkylamidino) phenyl]furans as anti-Pneumocystis carinii agents. J. Med. Chem., 1998, 41, 124-129.
124. Debs, R.J.; Blumenfeld, W.; Brunette, E.N.; Straubinger, R.M.; Montgomery, A.B.; Lin, E.; Agabian, N.; Papahadjopoulos, D. Successful treatment with aerosolized pentamidine of Pneumocystis carinii pneumonia in rats. Antimicrob. Agents Chemother., 1987, 31, 37-41.
125. Francesconi, I.; Wilson, W.D.; Tanious, F.A.; Hall, J.E.; Bender, B.C.; Tidwell, R.R.; McCurdy, D.; Boykin, D.W. 2,4-Diphenyl furan diamidines as novel anti-Pneumocystis carinii pneumonia agents. J. Med. Chem., 1999, 42, 2260-2265.
126. Girard, P.M.; Brun-Pascaud, M.; Farinotti, R.; Tamisier, L.; Kernbaum, S. Pentamidine aerosol in prophylaxis and treatment of murine Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother., 1987, 31, 978-981.
127. Hopkins, K.T.; Wilson, W.D.; Bender, B.C.; McCurdy, D.R.; Hall, J.E.; Tidwell, R.R.; Kumar, A.; Bajic, M.; Boykin, D.W. Extended aromatic furan amidino derivatives as anti-Pneumocystis carinii agents. J. Med. Chem., 1998, 41, 3872-3878.
128. Jones, S.K.; Hall, J.E.; Allen, M.A.; Morrison, S.D.; Ohemeng, K.A.; Reddy, V.V.; Geratz, J.D.; Tidwell, R.R. Novel pentamidine analogs in the treatment of experimental Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother., 1990, 34, 1026-1030
129. Montgomery, A.B.; Debs, R.J.; Luce, J.M.; Corkery, K.J.; Turner, J.; Brunette, E.N.; Lin, E.T.; Hopewell, P.C. Aerosolised pentamidine as sole therapy for Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Lancet, 1987, 2, 480-483.
130. Montgomery, A.B.; Debs, R.J.; Luce, J.M.; Corkery, K.J.; Turner, J.; Hopewell, P.C. Aerosolized pentamidine as second line therapy in patients with AIDS and Pneumocystis carinii pneumonia. Chest, 1989, 95, 747-750.
131. Reisner, H.M.; Gray, D.R.; Jones, S.K.; Rose, B.G.; Tidwell, R.R. Immunoassays for pentamidine and related compounds: Development of a facile inhibitory ELISA suitable for clinical use. J. Clin. Lab. Anal., 2000, 14, 73-82.
132. Tidwell, R.R.; Jones, S.K.; Geratz, J.D.; Ohemeng, K.A.; Bell, C.A.; Berger, B.J.; Hall, J.E. Development of pentamidine analogues as new agents for the treatment of Pneumocystis carinii pneumonia. Ann. N.Y. Acad. Sci., 1990, 616, 421-441.
133. Tidwell, R.R.; Jones, S.K.; Geratz, J.D.; Ohemeng, K.A.; Cory, M.; Hall, J.E. Analogues of 1,5-bis(4-amidinophenoxy)pentane (pentamidine) in the treatment of experimental Pneumocystis carinii pneumonia. J. Med. Chem., 1990, 33, 1252-1257.
134. Walzer, P.D.; Ashbaugh, A.; Collins, M.; Cushion, M.T. In vitro and in vivo effects of quinupristin-dalfopristin against Pneumocystis carinii. Antimicrob..Agents Chemother., 2001, 45, 3234-3237.
135. Walzer, P.D.; Kim, C.K.; Foy, J.; Linke, M.J.; Cushion, M.T. Cationic antitrypanosomal and other antimicrobial agents in the therapy of experimental Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother., 1988, 32, 896-905.
136. Walzer, P.D.; Foy, J.; Runck, J.; Steele, P.; White, M.; Klein, R.S.; Otter, B.A.; Sundberg, R.J. Guanylhydrazones in therapy of Pneumocystis carinii pneumonia in immunosuppressed rats. Antimicrob. Agents Chemother., 1994, 38, 572-2576.
137. Wood, D.H.; Hall, J.E.; Rose, B.G.; Boykin, D.W.; Tidwell, R.R. Pentamidine is a potent inhibitor of[3H]idazoxan binding to imidazoline I2 receptors. Ann. N.Y. Acad. Sci., 1999, 881, 110-113.
138. Wood, D.H.; Hall, J.E.; Rose, B.G.; Tidwell, R.R. 1,5-Bis(4-amidinophenoxy)pentane (pentamidine) is a potent inhibitor of[3H]idazoxan binding to imidazoline I2 binding sites. Eur. J. Pharmacol., 1998, 353, 97-103.
139. Bartlett, M.S.; Queener, S.F.; Tidwell, R.R.; Milhous, W.K.; Berman, J.D.; Ellis, W.Y.; Smith, J.W. 8-Aminoquinolines from walter reed army institute for research for treatment and prophylaxis of Pneumocystis pneumonia in rat models. Antimicrob. Agents Chemother., 1991, 35, 277-282.
140. Queener, S.F.; Bartlett, M.S.; Nasr, M.; Smith, J.W. 8-aminoquinolines effective against Pneumocystis carinii in vitro and in vivo. Antimicrob. Agents Chemother., 1993, 37, 2166-2172.
141. Queener, S.F.; Bartlett, M.S.; Richardson, J.D.; Durkin, M.M.; Jay, M.A.; Smith, J.W. Activity of clindamycin with primaquine against Pneumocystis carinii in vitro and in vivo. Antimicrob. Agents Chemother., 1988, 32, 807-813.
142. Queener, S.F.; Dean, R.A.; Bartlett, M.S.; Milhous, W.K.; Berman, J.D.; Ellis, W.Y.; Smith, J.W. Efficacy of intermittent dosage of 8-aminoquinolines for therapy or prophylaxis of Pneumocystis pneumonia in rats. J. Infect. Dis., 1992, 165, 764-768.
143. Smith, J.W.; Bartlett, M.S.; Queener, S.F.; Durkin, M.M.; Jay, M.A.; Hull, M.T.; Klein, R.S.; Marr, J.J. Pneumocystis carinii pneumonia therapy with 9-deazainosine in rats. Diagn. Microbiol. Infect. Dis., 1987, 7, 113-118.
144. Chin, K.; Merali,S.; Saric, M.; Clarkson, A.B.Jr. Continuous infusion of DL-alpha-difluoromethylornithine and improved efficacy against a rat model of Pneumocystis carinii pneumonia. Antimicrob. Agents Chemothe.r, 1996, 40, 2318-2320.
145. Clarkson, A.B.; Jr.; Williams, D.E.; Rosenberg, C. Efficacy of DL-alpha-difluoromethylornithine in a rat model of Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother., 1988, 32, 1158-1163.
146. Merali, S. Pneumocystis carinii polyamine catabolism. J. Biol. Chem., 1999, 274, 21017-21022.
147. Merali, S.; Chin, K.; Grady, R.W.; Clarkson, A.B.Jr. Clinically achievable plasma deferoxamine concentrations eliminate Pneumocystis carinii trophozoites in a rat model. J. Eukaryot. Microbiol., 1996, 43, 52S.
148. Merali, S.; Clarkson, A.B.; Jr. Polyamine content of Pneumocystis carinii and response to the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithine. Antimicrob. Agents Chemother., 1996, 40, 973-978.
149. Merali, S.; Saric, M.; Chin, K.; Clarkson, A.B. Jr. Effect of a bisbenzyl polyamine analogue on Pneumocystis carinii. Antimicrob. Agents Chemother., 2000, 44, 337-343.
150. Walzer, P.D.; Kim, C.K.; Foy, J.; Zhang.; J.L. Furazolidone and nitrofurantoin in the treatment of experimental Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother., 1991, 35, 158-163.
151. Bartlett, M.S.; Current, W.L.; Goheen, M.P.; Boylan, C.J.; Lee, C.H.; Shaw, M.M.; Queener, S.F.; Smith, J.W. Semisynthetic echinocandins
152. Furuta, T.; Muramatsu, H.; Fujie, A.; Fujihira, S. Therapeutic effect of a water soluble echinocandin compound on Pneumocystis pneumonia in animals. J. Eukaryot. Microbiol., 1997, 44, 53S
153. Furuta, T.; Muramatsu, H.; Fujie, A.; Fujihira, S.; Abudullah, N.R.; Kojima, S. Therapeutic effects of water-soluble echinocandin compounds on Pneumocystis pneumonia in mice. Antimicrob. Agents Chemother., 1998, 42, 37-39.
154. Ito, M.; Nozu, R.; Kuramochi, T.; Eguchi, N.; Suzuki, S.; Hioki, K.; Itoh, T.; Ikeda, F. Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice. Antimicrob. Agents Chemother., 2000, 44, 2259-2262
155. Powles, M.A.; Liberator, P.; Anderson, J.; Karkhanis, Y.; Dropinski, J.F.; Bouffard, J.; Balkovec, J.M.; Fujioka, H.; Aikawa, M.; McFadden, D.; Schmatz, D. Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob. Agents Chemother., 1998, 42, 1985-1989.
156. Schmatz, D. M.; Powles, M.A.; McFadden, D.C.; Pittarelli, L.; Balkovec, J.; Hammond, M.; Zambias, R.; Liberator, P.; Anderson, J. Antipneumocystis activity of water-soluble lipopeptide L-693,989 in rats. Antimicrob. Agents Chemother., 1992, 36, 1964-1970.
157. Jimenez, E.; Martinez, A.; Aliouat, E.M.; Caballero, J.; Dei-Cas, E.; Gargallo-Viola, D. Therapeutic efficacies of GW471552 and GW471558, two new azasordarin derivatives, against pneumocystosis in two immunosuppressed-rat models. Antimicrob. Agents Chemother., 2002, 46, 2648-2650.
158. Contini, C.; Angelici, E.; Canipari, R. Structural changes in rat Pneumocystis carinii surface antigens after terbinafine administration in experimental P. carinii pneumonia. J. Antimicrob. Chemothe.r, 1999, 43, 301-304.
159. Brun-Pascaud, M.; Fay, M.; Zhong, M.; Bauchet, J.; Dux-Guyot, A.; Pocidalo, J.J. Use of fluoroquinolones for prophylaxis of murine Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother., 1992, 36, 470-472.
160. Comley, J.C.; Yeates, C.L.; Frend, T.J. Antipneumocystis activity of 17C91, a prodrug of atovaquone. Antimicrob. Agents Chemother., 1995, 39, 2217-2219.
161. Hughes, W.T.; Gray, V.L.; Gutteridge, W.E.; Latter, V.S.; Pudney, M. Efficacy of a hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis. Antimicrob. Agents Chemother., 1990, 34, 225-228.
162. Walzer, P.D.; Runck, J.; Orr, S.; Foy, J.; Steele, P.; White, M. Clinically used antimicrobial drugs against experimental pneumocystosis, singly and in combination: Analysis of drug interactions and efficacies. Antimicrob. Agents Chemother., 1997, 41, 242-250
163. Oz, H.S.; Hughes, W.T.; Rehg, J.E. Efficacy of lasalocid against murine Pneumocystis carinii pneumonitis. Antimicrob. Agents Chemother., 1997, 41, 191-192.
164. Yasuoka, A.; Oka, S.; Komuro, K.; Shimizu, H.; Kitada, K.; Nakamura, Y.; Shibahara, S.; Takeuchi, T.; Kondo, S.; Shimada, K. Successful treatment of Pneumocystis carinii Pneumonia in mice with benanomicin A (ME1451). Antimicrob. Agents Chemother., 1995, 39, 720-724.
165. Clarkson, A.B.; Jr.;Saric, M.; Grady, R.W. Deferoxamine and eflornithine (DL-alpha-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother., 1990, 34, 1833-1835.
166. Merali, S.; Chin, K.; Del Angel, L.; Grady, R.W.; Armstrong, M.; Clarkson, A.B.Jr. Clinically achievable plasma deferoxamine concentrations are therapeutic in a rat model of Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother., 1995, 39, 2023-2026.
167. Merali, S.; Chin, K.; Grady, R.W.; Weissberger, L.; Clarkson, A.B.;Jr. Response of rat model of Pneumocystis carinii pneumonia to continuous infusion of deferoxamine. Antimicrob. Agents Chemother., 1995, 39, 1442-1444.
168. Beck, J.M.; Liggitt, H.D.; Brunette, E.N.; Fuchs, H.J.; Shellito, J.E.; Debs, R.J. Reduction in intensity of Pneumocystis carinii pneumonia in mice by aerosol administration of gamma interferon. Infect. Immun., 1991, 59, 3859-3862.
169. Empey, K.M.; Hollifield, M.; Schuer, K.; Gigliotti, F.; Garvy, B.A. Passive immunization of neonatal mice against Pneumocystis carinii f. sp. muris enhances control of infection without stimulating inflammation. Infect. Immun., 2004, 72, 6211-6220
170. Gigliotti, F.; Hughes, W.T. Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis in animal models. J. Clin. Invest., 1988, 81, 1666-1668.
171. Lee, M.; Cho, S.R.; Park, Y.K.; Choi, M.H.; Hong, S.T. The effect of heterogeneous hyperimmune IgG antibody on prophylaxis and treatment of Pneumocystis carinii infection in rats. Korean J. Parasitol., 1998, 36, 127-132.
172. Mandujano, J.F.; D'Souza, N.B.; Nelson, S.; Summer, W.R.; Beckerman, R.C.; Shellito, J.E. Granulocyte-macrophage colony stimulating factor and Pneumocystis carinii pneumonia in mice. Am. J. Respir. Crit. Care Med., 1995, 151, 1233-1238.
173. Rapaka, R.R.; Goetzman, E.S.; Zheng, M.; Vockley, J.; McKinley, L.; Kolls, J.K.; Steele, C. Enhanced defense against Pneumocystis carinii mediated by a novel dectin-1 receptor Fc fusion protein. J. Immunol., 2007, 178, 3702-3712.
174. Shear, H.L.; Valladares, G.; Narachi, M.A. Enhanced treatment of Pneumocystis carinii pneumonia in rats with interferon-gamma and reduced doses of trimethoprim/sulfamethoxazole. J. Acquir. Immune Defic. Syndr., 1990, 3, 943-948.
175. Smulian, A.G.; Sullivan, D.W.; Theus, S.A. Immunization with recombinant Pneumocystis carinii p55 antigen provides partial protection against infection: Characterization of epitope recognition associated with immunization. Microbes. Infect., 2000, 2, 127-136
176. Theus, S.A.; Andrews, R.P.; Steele, P.; Walzer, P.D. Adoptive transfer of lymphocytes sensitized to the major surface glycoprotein of Pneumocystis carinii confers protection in the rat. J. Clin. Invest., 1995, 95, 2587-2593.
177. Theus, S.A.; Smulian, A.G.; Steele, P.; Linke, M.J.; Walzer, P.D. Immunization with the major surface glycoprotein of Pneumocystis carinii elicits a protective response. Vaccine, 1998, 16, 1149-1157.
178. Wells, J.; Haidaris, C.G.; Wright, T.W.; Gigliotti, F. Active Immunization against Pneumocystis carinii with a Recombinant P. carinii Antigen. Infect. Immun., 2006, 74, 2446-2448.
179. Wells, J.; Haidaris, C.G.; Wright, T.W.; Gigliotti, F. Complement and Fc Function Are Required for Optimal Antibody Prophylaxis against Pneumocystis carinii Pneumonia. Infect. Immun., 2006, 74, 390-393.
180. De Lucca, A.J.; Bland, J.M.; Vigo, C.B.; Cushion, M.; Selitrennikoff, C.P.; Peter, J.; Walsh, T.J. CAY-I, a fungicidal saponin from Capsicum sp. fruit. Med. Mycol., 2002, 40, 131-137.
181. Brun-Pascaud, M.; Chau, F. Derouin, F.; Girard, P.M. Experimental evaluation of roxithromycin combined with dapsone or sulphamethoxazole on Pneumocystis carinii and Toxoplasma gondii dual infections in a rat model. J. Antimicrob. Chemother., 1998, 41(Suppl B), 57-62.
182. Brun-Pascaud, M.; Chau, F.; Garry, L.; Farinotti, R.; Derouin, F.; Girard, P.M. Altered trimethoprim-sulfamethoxazole ratios for prophylaxis and treatment of Toxoplasma gondii and Pneumocystis carinii dual infections in rat model. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol., 1996, 13, 201-207.
183. Brun-Pascaud, M.; Chau, F.; Garry, L.; Jacobus, D.; Derouin, F.; Girard, P.M. Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model. Antimicrob. Agents Chemother., 1996, 40, 2067-2070.
184. Brun-Pascaud, M.; Rajagopalan-Levasseur, P.; Chau, F.; Bertrand, G.; Garry, L.; Derouin, F.; Girard. P.M. Drug evaluation of concurrent Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium complex infections in a rat model. Antimicrob. Agents Chemother., 1998, 42, 1068-1072.
185. Oz, H.S.; Hughes, W.T.; Varilek, G.W. A rat model for combined Trypanosoma cruzi and Pneumocystis carinii infection. Microb. Pathog., 2000, 29, 363-365.
186. Beltz, K.; Kramm, C.M.; Laws, H.J.; Schroten, H.; Wessalowski, R.; Gobel, U. Combined trimethoprim and caspofungin treatment for severe Pneumocystis jiroveci pneumonia in a five year old boy with acute lymphoblastic leukemia. Klin. Padiatr., 2006, 218, 177-179.
187. Kamboj, M.; Weinstock, D.; Sepkowitz, K.A. Progression of Pneumocystis jiroveci pneumonia in patients receiving echinocandin therapy. Clin. Infect. Dis., 2006, 43, e92-e94.
188. Utili, R.; Durante-Mangoni, E.; Basilico, C.; Mattei, A.; Ragone, E.; Grossi, P. Efficacy of caspofungin addition to trimethoprimsulfamethoxazole treatment for severe pneumocystis pneumonia in solid organ transplant recipients. Transplantation, 2007, 84, 685-688.
189. Waters, L.; Nelson, M. The use of caspofungin in HIV-infected individuals. Expert Opin. Investig. Drugs, 2007, 16, 899-908.
190. Smulian, A.G.; Sesterhenn, T.; Tanaka, R.; Cushion, M.T. The ste3 pheromone receptor gene of Pneumocystis carinii is surrounded by a cluster of signal transduction genes. Genetics 2001, 157, 991-1002.
191. Bartlett, M.S.; Marr, J.J.; Queener, S.F.; Klein, R.S.; Smith, J.W. Activity of inosine analogs against Pneumocystis carinii in culture. Antimicrob. Agents Chemother., 1986, 30, 181-183.
192. Bartlett, M.S.; Queener, S.F.; Shaw, M.M.; Richardson, J.D.; Smith, J.W. Pneumocystis carinii is resistant to imidazole antifungal agents. Antimicrob. Agents Chemother., 1994, 38, 1859-1861.
193. Queener, S.F.; Fujioka, H.; Nishiyama, Y.; Furukawa, H.; Bartlett, M.S.; Smith, J.W. In vitro activities of acridone alkaloids against Pneumocystis carinii. Antimicrob. Agents Chemother., 1991, 35, 377-379.
194. Ittarat, I.; Asawamahasakda, W.; Bartlett, M.S.; Smith, J.W.; Meshnick, S.R. Effects of atovaquone and other inhibitors on Pneumocystis carinii dihydroorotate dehydrogenase. Antimicrob. Agents Chemother., 1995, 39, 325-328.
195. Comley, J.C.; Sterling.; J.M. Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice. Antimicrob Agents Chemother, 1995, 39, 806-811.
196. Contini, C.; Colombo, D.; Cultrera, R.; Prini, E.; Sechi, T.; Angelici, E.; Canipari, R. Employment of terbinafine against Pneumocystis carinii infection in rat models. Br. J. Dermatol., 1996, 134(Suppl 46), 30-32.
197. Pifer, L.L. A fifteen-year perspective on the in vitro culture of Pneumocystis carinii. J. Protozool., 1989, 36, 23S-24S.
198. Comley, J.C.; Mullin, R.J.; Wolfe, L.A.; Hanlon, M.H.; Ferone, R. Microculture screening assay for primary in vitro evaluation of drugs against Pneumocystis carinii. Antimicrob. Agents Chemother., 1991, 35, 1965-1974.
199. Fujie, A.; Iwamoto, T.; Muramatsu, H.; Okudaira, T.; Nitta, T. Nakanishi, T.; Sakamoto, K.; Hori, Y.; Hino, M.; Hashimoto, S.; Okuhara, M. FR901469, a novel antifungal antibiotic from an unidentified fungus No.11243. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological properties. J. Antibiot, (Tokyo) 2000, 53, 912-919.
200. Oz, H.S.; Hughes, W.T.; Rehg, J.E. Rat model for dual opportunistic pathogen prophylaxis: Cryptosporidium parvum and Pneumocystis carinii. Lab. Anim. Sci., 1999, 49, 331-334.
201. Tantisiriwat, W.; Powderly, W.G.; Prophylaxis and treatment of opportunistic infection in patients on HAART. AIDS Read, 1999, 9, 122-130.